Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

Rhea-AI Summary

Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has scheduled its Q1 2025 financial results announcement for May 7, 2025, after market close.

The company's senior management team will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss:

• First quarter 2025 financial performance
• Updates on corporate progress

Investors and interested parties can access the live webcast through the company's investor relations website at ir.revmed.com/events-and-presentations. A replay of the webcast will remain available on the website for at least 14 days following the live presentation.

Positive

• Late-stage clinical status indicates advanced development progress in oncology therapeutics
• Focus on targeted therapies for RAS-addicted cancers shows clear market positioning

Negative

• None.

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

FAQ

When will Revolution Medicines (RVMD) release Q1 2025 earnings?

Revolution Medicines (RVMD) will release its Q1 2025 financial results on Wednesday, May 7, 2025, after the market closes.

What time is Revolution Medicines (RVMD) Q1 2025 earnings call?

Revolution Medicines will host its Q1 2025 earnings webcast at 4:30 p.m. ET (1:30 p.m. PT) on May 7, 2025.

How can I listen to RVMD's Q1 2025 earnings webcast?

Investors can access RVMD's Q1 2025 earnings webcast at https://ir.revmed.com/events-and-presentations. A replay will be available for at least 14 days after the live event.

What will Revolution Medicines discuss in their May 7 earnings call?

Revolution Medicines' senior management team will discuss Q1 2025 financial results and provide updates on corporate progress during the earnings call.

What type of cancer treatments does Revolution Medicines (RVMD) develop?

Revolution Medicines develops targeted therapies specifically for patients with RAS-addicted cancers, operating as a late-stage clinical oncology company.